Fidan, M.C.; Öztürk, A.E.; Aydın, O.; Akdağ, G.; Türkoğlu, E.; Çolak, R.; Majidova, N.; Kapağan, T.; Guliyev, M.; Çelik, E.;
et al. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data. J. Clin. Med. 2025, 14, 4568.
https://doi.org/10.3390/jcm14134568
AMA Style
Fidan MC, Öztürk AE, Aydın O, Akdağ G, Türkoğlu E, Çolak R, Majidova N, Kapağan T, Guliyev M, Çelik E,
et al. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data. Journal of Clinical Medicine. 2025; 14(13):4568.
https://doi.org/10.3390/jcm14134568
Chicago/Turabian Style
Fidan, Mehmet Cem, Ahmet Emin Öztürk, Okan Aydın, Goncagül Akdağ, Ezgi Türkoğlu, Rumeysa Çolak, Nargiz Majidova, Tanju Kapağan, Murad Guliyev, Emir Çelik,
and et al. 2025. "First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data" Journal of Clinical Medicine 14, no. 13: 4568.
https://doi.org/10.3390/jcm14134568
APA Style
Fidan, M. C., Öztürk, A. E., Aydın, O., Akdağ, G., Türkoğlu, E., Çolak, R., Majidova, N., Kapağan, T., Guliyev, M., Çelik, E., Odabaş, H., Yılmaz, M., Bayoğlu, İ. V., Bulut, N., Demirci, N. S., & Alan, Ö.
(2025). First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data. Journal of Clinical Medicine, 14(13), 4568.
https://doi.org/10.3390/jcm14134568
